Abstract
The published literature suggests that less than 25% of patients with de novo acute myeloblastic leukaemia (AML), treated by intensive chemotherapy, are cured by this approach [1, 2]. Modest improvements have been claimed for treatment on high-dose cytosine arabinoside (HD-Ara-C) containing combinations [3] and in younger patients on the VAPA protocol [4]. As a rule more than 60% experience disease recurrence [5, 2].
Keywords
- Minimal Residual Disease
- Conditioning Regimen
- Cytosine Arabinoside
- Acute Myeloblastic Leukaemia
- Royal Free Hospital
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Rees JKH, Gray RG et al. (1986) Lancet ii: 1236–1241
Preisler HD, Anderson K, Cuttner J et al. (1987) Br J Haematol 71: 189–194
Wolff SN, Herzig AW, Phillips GL et al. (1987) Semin Oncol 14: 12–17
Weinstein JH, Mayer RJ, Rosenthal DS et al. (1983) Blood 62: 315–319
Garson OM, Hagemcijer A, Sakurai M et al. (1989) Cancer Genet Cytogenet 40: 187–202
International Bone Marrow Transplant Registry (1989) Lancet i: 1119–1122
Gratwohl A, Hermans J, Barrett AJ et al. (1988) Lancet i: 1379–1382
Pollard, CM, Powles RL, Miller JL (1986) Lancet ii: 1343–1344
Atkinson K, Biggs J, Dodds A et al. (1988) Aust NZ J Med 18: 587–593
Maraninchi D, Gluckman E, Blaise D (1986) Lancet ii: 175–178
Weiden PL, Fluornoy N, Thomas ED et al. (1979) N Engl J Med 300: 1068–1073
Clift RA, Buckner CD, Appelbaum FR et al. (1990) Blood 76: 1867–1871
Clift RA, Buckner CD, Appelbaum FR et al. (1990) Blood 76: 1867–1871
Burnett AK, Hann IM, Robertson AG et al. (1988) Leukaemia 2: 300–303
Ash RC, Jasper D, Lawton CG et al. (1989) Blood 74(1): 163 (abstr)
Schattenberg A, De Witte T, Bar B et al. (1989) Bone Marrow Tansplant 4 [Suppl 1]: 111
Reittie JE, Gottlieb DJ, Heslop HE et al. (1989) Blood 73: 1351–1358
Hercend T, Reinherz ELK, Meuer SC et al. (1983) Nature 301: 158–160
Price G, Brenner MK, Prentice HG et al. (1989) Br J Cancer 71: 189–194
Heslop HE, Gottlieb DJ, Reittie JE et al. (1989) Br J Haematol 72: 122–126
Kiyohara T, Taniguchi K, Kubota S et al. (1988) J Exp Med 168: 2355–2360
Leger O, Drexler HG, Reittie JE, et al. (1987) Br J Haematol 67: 273–279
Gottlieb DJ, Brenner MK, Heslop HE et al. (1989) Br J Cancer 60: 610–615
Gottlieb DJ, Prentice HG, Heslop HE et al. (1988) Blood 74: 2335–2342
Foa R, Fierro MT, Tosti S et al. (1990) Leuk Lymph 1: 113–117
MacDonald D, Jiang YZ, Swirsky D et al. (1991) Br J Haematol 77: 43–49
Carron JA, Cawley JC (1989) Br J Haematol 73: 168
Foa R, Caretto P, Fierro NT (1990) Br J Haematol 75: 34–40
Geller RB, Saral R, Karp JE et al. (1990) Leukemia 4: 313–315
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Prentice, H.G. (1992). Understanding the Mechanisms of Cure in Acute Myeloblastic Leukaemia: Towards a Modern Immunotherapy. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_98
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_98
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive